United States - Patent - FDA Approves First Two Interchangeable EYLEA® Biosimilars – Biocon's Yesafili™ (Aflibercept-jbvf) And Samsung Bioepis's Opuviz™ (Aflibercept-yszy) mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.
Welcome to this issue of The Precedent, which covers those opinions from Q3 and Q4 of 2023 that the Federal Circuit designated as precedential and worthy of publication in the Federal Reporter.
FDA Approves First Two Interchangeable EYLEA® Biosimilars – Biocon's Yesafili™ (aflibercept-jbvf) and Samsung Bioepis's Opuviz™ (aflibercept-yszy) | Venable LLP jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
In denying Petitioner Medivis, Inc.'s ("Medivis") Request for Rehearing of the Patent Trial and Appeal Board's ("PTAB") Final Written Decision ("FWD") in
Higher Burden of Demonstrating Public Accessibility of a Reference at Final Decision Stage | Jones Day jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.